Research programme: eye disorders therapy - CSL
Alternative Names: Recombinant antibody therapeutics research programme - CSLLatest Information Update: 19 Apr 2010
At a glance
- Originator CSL
- Developer CSL; Flinders University
- Class Antibodies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 13 Jul 2007 Late-stage preclinical development is ongoing
- 05 Oct 2004 Preclinical trials in Eye disorders in Australia (Ophthalmic)